Detection of relapse after hematopoietic stem cell transplantation in childhood by monitoring of WT1 expression and chimerism

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 7, 2015, Pages 1283-1290

  Woehlecke, Caroline ^a   Wittig, Susan ^a   Sanft, Juliane ^a   Kreyenberg, Hermann ^b   Gruhn, Bernd ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Acute myeloid leukemia (AML); Chimerism; Hematopoietic stem cell transplantation (HSCT); Minimal residual disease (MRD); Myelodysplastic syndrome (MDS); WT1 expression

Indexed keywords

ADOLESCENT; ADULT; CHILD; CHIMERA; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PATHOLOGY; PRESCHOOL CHILD; RECURRENT DISEASE; TUMOR SUPPRESSOR GENE; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHIMERISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, WILMS TUMOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; NEOPLASM, RESIDUAL; RECURRENCE; YOUNG ADULT;

EID: 84938512754     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-1919-0     Document Type: Article

References (25)

1. Bader P, Holle W, Klingebiel T, Handgretinger R, Niethammer D, Beck J (1996) Quantitative assessment of mixed hematopoietic chimerism by polymerase chain reaction after allogeneic BMT. Anticancer Res 16:1759–1763
2. Bader P et al (2004a) Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol Off J Am Soc Clin Oncol 22:1696–1705. doi:10.1200/JCO.2004.05.198
3. Bader P et al (2004b) WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia? Eur J Haematol 73:25–28. doi:10.1111/j.1600-0609.2004.00260.x
4. Bader P, Willasch A, Klingebiel T (2008) Monitoring of post-transplant remission of childhood malignancies: is there a standard? Bone Marrow Transpl 42(Suppl 2):S31–S34. doi:10.1038/bmt.2008.280
5. Boublikova L et al (2006) Wilms’ tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 20:254–263. doi:10.1038/sj.leu.2404047
6. Candoni A, Toffoletti E, Gallina R, Simeone E, Chiozzotto M, Volpetti S, Fanin R (2011) Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin Transpl 25:308–316. doi:10.1111/j.1399-0012.2010.01251.x
7. Christopeit M, Kroger N, Haferlach T, Bacher U (2014) Relapse assessment following allogeneic SCT in patients with MDS and AML. Ann Hematol. doi:10.1007/s00277-014-2046-8
8. Collins RH Jr et al (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol Off J Am Soc Clin Oncol 15:433–444
9. Elmaagacli AH, Beelen DW, Trenschel R, Schaefer UW (2000) The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transpl 25:91–96. doi:10.1038/sj.bmt.1702095
10. Eva Rettinger AMW, Kreyenberg H, Borkhardt A, Holter W, Kremens B, Strahm B, Woessmann W, Mauz-Koerholz C, Gruhn B, Burdach S, Albert MH, Schlegel P-G, Klingebiel T, Bader P (2011) Preemptive immunotherapy in childhood acute myeloid leukemia for patients. Blood 118:5681–5688. doi:10.1182/blood-2011-04-348805
11. Hashii Y, Sato E, Ohta H, Oka Y, Sugiyama H, Ozono K (2010) WT1 peptide immunotherapy for cancer in children and young adults. Pediatr Blood Cancer 55:352–355. doi:10.1002/pbc.22522
12. Inoue K et al (1996) Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 88:2267–2278
13. Jacobsohn DA et al (2009) High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival. Br J Haematol 146:669–674. doi:10.1111/j.1365-2141.2009.07770.x
14. Justyna Jólkowska KD, Dawidowska Malgorzata (2007) Methods of minimal residual disease (MRD) detection in childhood haematological malignancies. J Appl Genet 48:77–83
15. Kletzel M, Olzewski M, Huang W, Chou PM (2002) Utility of WT1 as a reliable tool for the detection of minimal residual disease in children with leukemia. Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc 5:269–275. doi:10.1007/s10024001-0208-x
16. Kwon M et al (2012) Evaluation of minimal residual disease by real-time quantitative PCR of Wilms’ tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl 18:1235–1242. doi:10.1016/j.bbmt.2012.01.012
17. Lange T et al (2011) Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 25:498–505. doi:10.1038/leu.2010.283
18. Ogawa H et al (2003) The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 101:1698–1704. doi:10.1182/blood-2002-06-1831
19. Pozzi S et al (2013) Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression. Br J Haematol 160:503–509. doi:10.1111/bjh.12181
20. Pulsipher MA, Bader P, Klingebiel T, Cooper LJ (2009) Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl 15:62–71. doi:10.1016/j.bbmt.2008.11.009
21. Roux E, Helg C, Chapius B, Jeannet M, Roosnek E (1994) Mixed chimerism after bone marrow transplantation and the risk of relapse. Blood 84:4385–4386
22. Weber G et al (2009) WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. Leukemia 23:1634–1642. doi:10.1038/leu.2009.70
23. Willasch AM et al (2009) Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia 23:1472–1479. doi:10.1038/leu.2009.51
24. Woehlecke C, Wittig S, Arndt C, Gruhn B (2014) Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseases. J Cancer Res Clin Oncol. doi:10.1007/s00432-014-1832-y
25. Zhao XS et al (2012) Wilms’ tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. Bone Marrow Transpl 47:499–507. doi:10.1038/bmt.2011.121